Hospitals open new specialist centres. Clinic groups expand into new cities. Public health programmes reach large numbers of people. Medical technology companies enter new markets, and wellness brands build distribution networks across the region. Many of these organisations also receive accreditations, industry awards or record recognition along the way.

Sharing these achievements is a normal part of building an institution. In healthcare, though, a factual announcement can easily become a misleading claim. A statement about scale can be read as a statement about quality. An award can be taken as proof that a treatment works. Several regulators across Asia take that risk seriously.

This article explains how different types of healthcare claims should be treated, outlines what selected frameworks in Singapore and Malaysia require, and sets out a practical checklist for organisations preparing to publicise an achievement.

Why Healthcare Claims Are Held to a Different Standard

Most consumers cannot independently judge whether a hospital’s surgical results are good, whether a supplement does what its label suggests, or whether a clinic’s technology is appropriate for their condition. That information gap is why healthcare promotion is regulated more tightly than promotion in most other sectors.

The international baseline is long-standing. In 1988 the World Health Assembly endorsed the World Health Organization’s Ethical Criteria for Medicinal Drug Promotion, a reference framework for judging proper conduct in drug promotion. The criteria are general principles for governments to adapt to national circumstances rather than binding law. Their core idea still underpins much of the region’s regulation: promotion should support rational, informed health decisions rather than simply drive consumption.

National rules turn that principle into specific obligations, and those obligations differ by country and by the type of product or service involved.

Five Types of Claims Healthcare Organisations Make

Before looking at regulation, it helps to separate the kinds of statements organisations actually make. Each carries a different evidential burden. The examples below are illustrative.

Claim type	Illustrative wording	What it can legitimately communicate	Evidence expected	Regulatory sensitivity
Descriptive fact	“We opened a new cardiac centre this year.”	That something exists or happened	Internal records, licences, public filings	Low to moderate
Operational or scale achievement	“Our programme delivered community screenings across several states.”	Reach, volume, participation or growth	Auditable counts, defined units, dates and scope	Moderate
Recognition claim	“Accredited by…”, “Winner of…”, “Recognised by…”	That a third party assessed something against its own criteria	The recognising body’s criteria, scope and date	Moderate to high (restricted in some markets)
Comparative or superlative claim	“The largest…”, “No. 1…”, “The first…”	A ranking against others	A defensible, bounded comparison with a clear basis	High
Clinical or efficacy claim	“Our treatment produces better outcomes.”	That an intervention benefits patients	Robust clinical evidence and, where required, regulatory approval	Very high

Problems usually arise when one type of claim is presented as another. A verified operational milestone gets worded so that readers infer a clinical benefit, or an award for service design is presented as evidence of treatment quality.

What Regulators in the Region Look For

Singapore: Recognition Is Itself a Regulated Message

Singapore’s Healthcare Services (Advertisement) Regulations 2021, made under the Healthcare Services Act 2020, came into operation on 3 January 2022. They set content requirements for advertisements of licensable healthcare services, including that information be factually accurate, capable of substantiation, and not exaggerated or misleading.

Two provisions are especially relevant to organisations that want to publicise achievements:

• Regulation 13 states that, except as the regulation provides, a licensee must not display or publicise information about any accreditation, certification, award, prize or other honour conferred in relation to its licensable healthcare services. The exceptions are narrow. Recognition that would be routine publicity material in other industries therefore needs careful checking before a licensee uses it.
• Regulation 14 applies a similar default restriction to reviews, testimonials and endorsements, subject to limited exceptions.

The Regulations also restrict certain hyperlinks on a licensee’s website and require licensees to take reasonable steps to correct non-compliant advertisements. The Ministry of Health has explained that the overall aim is to help the public make informed choices rather than to unduly influence them. Registered doctors are additionally bound by the Singapore Medical Council’s ethical code, which sets parallel expectations on advertising conduct.

Malaysia: Approval Comes Before Publication

In Malaysia, the Medicines (Advertisement and Sale) Act 1956 and the Medicine Advertisements Board (MAB) govern advertisements relating to medicines and medical and health services. According to the Ministry of Health, advertising approval under section 4A is available to private clinics, private hospitals, private medical laboratories and private radiological clinics operated by registered medical practitioners. Approved advertisements carry a KKLIU number that must be displayed clearly.

The Ministry also distinguishes two separate processes. Product registration addresses quality, safety and efficacy. MAB approval covers the advertisement itself. Holding one does not remove the need for the other.

The MAB’s 2015 guideline on advertising medicines and medicinal products to the public, which covers categories such as registered medicines, supplements and traditional products, is directly relevant to achievement messaging:

• Claims about objectively ascertainable facts should be capable of substantiation, and statistical claims should be supported by Malaysian data unless such data is unavailable.
• Its list of disallowed terms includes “No. 1” and percentages unless substantiated, along with “the best”, “only”, “most”, “unique” and “superior”.
• References to tests or trials at a named hospital or institution are permitted only with that institution’s authorisation.
• Testimonials are subject to conditions, including consent documentation and a statement that effects may vary among individuals.

Guidelines are updated over time, so organisations should confirm the current version with the Board before relying on any specific provision.

Beyond These Two Markets

Other Asian jurisdictions apply their own rules to medicines, devices, health supplements and healthcare services. A claim cleared in one country does not automatically carry across borders. Medical technology companies face an additional layer of device-specific requirements, discussed in our analysis of medical device regulation and market entry in Asia.

Where Awards and Record Recognition Fit

Accreditations, awards and records answer different questions. Accreditation typically assesses an organisation against defined standards. Awards usually reflect a judging panel’s assessment against competition criteria. Records document a specific, measurable result. Our earlier analysis of what each type of healthcare recognition actually proves examines these differences in detail.

Record recognition can be particularly relevant for healthcare businesses, hospital groups and health initiatives whose achievement lies in measurable scale, such as the size of a programme, the extent of a distribution network or the number of sites opened. Asia Record, for example, describes a process of comparing a clearly defined record claim with supporting evidence and the conditions needed to measure it consistently. Its published verification process reviews submissions for completeness, consistency, measurability, standardisation, verifiability and ethical execution.

That kind of bounded, evidence-based claim is structurally different from an open-ended superlative such as “the best clinic”. It states what was achieved, by whom, when, and by what measure. For an Asia Record holder, the accurate way to communicate the recognition is to repeat the record’s defined scope precisely and not expand it.

Three limits should be stated plainly:

1. Recognition is not clinical evidence. A record for the scale of a wellness programme, the reach of a product or the size of a facility says nothing about whether a treatment or product is effective or safe.
2. Recognition is not regulatory approval. The phrase “record certification” in Asia refers to verification of a measurable achievement. It does not replace product registration, advertising approval, facility licensing, accreditation, halal certification or any other legal requirement.
3. Publicising recognition may itself be regulated. In Singapore, for instance, displaying honours relating to licensable healthcare services is restricted by default. Whether a particular regulator accepts a recognition as substantiation for a comparative claim is a separate question for that regulator.

The same discipline applies to broader business achievement recognition in Asia. Business awards, company recognition and entrepreneur recognition programmes can reflect genuine commercial accomplishments, such as expansion, distribution reach or organisational growth. For healthcare and wellness companies, those Asian business achievements should be described in commercial terms and kept clearly separate from product performance.

For organisations considering how to get an Asia Record for an institutional milestone, the sequence matters. Define the achievement precisely, establish how it will be measured, and assemble evidence before preparing an Asia Record application. Communications planning comes after that, with compliance review. Organisations that apply for Asia Record recognition, or for any comparable award, should decide at the outset how the result would be communicated within the rules of each market where they operate.

Common Mistakes in Healthcare Achievement Messaging

• Converting scale into efficacy. Moving from “widely distributed” to “proven to work” is a leap that popularity, sales volume and recognition cannot support.
• Dropping the qualifiers. A recognition limited to a category, a year or a country becomes misleading when shortened to an unqualified “leading” or “number one”.
• Stretching recognition across services. An honour tied to one department, programme or product should not be presented as applying to the whole organisation.
• Reusing claims across borders. Wording approved in one jurisdiction may breach rules in another.
• Treating press releases and social posts as exempt. Advertising definitions in the region are generally broad and can capture websites, social media and advertorials.
• Borrowing professional authority. Malaysia’s guideline cautions against imagery or statements that give the impression of professional endorsement, such as the use of white coats or stethoscopes, where that implies a product is recommended by healthcare professionals.

A Pre-Publication Checklist

Before announcing any healthcare achievement, communications, medical and compliance teams can work through the following steps together:

1. Write the achievement in one precise sentence. Include the unit of measurement, the time period, the geography and the scope.
2. Classify the claim. Decide whether it is descriptive, operational, recognition-based, comparative or clinical, then apply the corresponding evidence standard.
3. Match evidence to wording. Every figure and qualifier should trace back to a document the organisation can produce on request.
4. Remove implied clinical claims. Read the draft as a patient would and delete language that suggests better outcomes unless separate clinical evidence supports it.
5. Check each jurisdiction’s rules. Confirm whether advertising approval is required and whether honours, testimonials and hyperlinks are restricted.
6. Keep an evidence file. Store source data, recognition letters, approval numbers and review sign-offs together.
7. Assign accountable sign-off. Clinical claims need medical review, and regulated advertising needs compliance or legal review.
8. Schedule a review date. Approvals can expire (an MAB approval certificate is valid for three calendar years unless otherwise specified), and records and rankings can be surpassed.

What This Means for Healthcare Leaders

Credible achievement messaging is not about saying less. It is about saying exactly what happened, in terms the evidence supports and the regulator permits. That discipline protects patients from being misled, and it protects organisations from enforcement action and reputational damage. It also lends more weight to the achievements they do announce.

For growing healthcare companies in particular, a record of precise, verifiable public statements becomes a form of institutional credibility in its own right, a theme explored further in our look at how healthtech companies can build credibility before scaling across Asia.

Note: This article provides general information on healthcare advertising frameworks and is not legal or regulatory advice. Requirements differ by jurisdiction, product category and service type, and they change over time. Organisations should confirm current obligations with the relevant authorities or qualified advisers before publishing.